Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s.
The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News.
